treatments with a power of 80%. Thirty-six patients were planned
for enrollment to ensure at least 30 patients completed the study.
The primary efficacy endpoint was the between-treatment
differences in total PG AUC0–2h during the MMTT for C300/
C300 compared with PBO/PBO. The secondary efficacy endpoints
included the between-group difference in PG ΔAUC0–2h
for C300/C300 compared with C300/PBO, and for C300/C150
compared with C300/PBO.
A mixed-effects model was used with sequence, period,
and treatment as fixed effects and patient as a random effect.
Hypothesis testing was performed for the pre-specified
comparison of total PG AUC and PG ΔAUC using a one-sided
level of significance of 2.5%. Between-treatment comparisons
for Treatments B–D were tested using a similar mixed-effects
model, with a two-sided 5% level of significance. No adjustments
for multiplicity were made. Between-treatment comparisons
with descriptive statistics are provided for plasma
insulin AUC, C-peptide AUC, and UGE